MegaPro Biomedical MPB-1734 Receives Composition Patent for New Dosage Form of Cancer Drug That Enhances Combination Immunotherapy

EQS Newswire / 11/15/2022 / 10:41 GMT+8

MegaPro Biomedical (6827) Press release on MegaPro Biomedical receiving a composition patent for MPB-1734, a new 505(b)(2) cancer drug formulation.

Release date: November 152022

MegaPro Biomedical MPB-1734 Receives Composition Patent for New Dosage Form of Cancer Drug That Enhances Combination Immunotherapy

MegaPro Biomedical Co., Ltd. (hereinafter referred to as “MegaPro”, Taiwan’s OTC stock code: 6827) announces that the product MPB-1734, a new dosage form of cancer drug under its nano-micelle technology platform, has officially obtained the Notice of Allowance for his US composition patent. Additionally, MPB-1734 has been approved by the FDA (US) and TFDA (Taiwan) for Phase 1/2a clinical trials, and two subjects have been enrolled so far.

Dr. Yuan-Hung Hsu, Executive Vice President of MegaPro Biomedical, says that based on the unique nano-micelle technology, poorly water-soluble hydrophobic drugs can be stably dispersed in water while increasing its solubility by more than 1000 times, which an intravenous injection medical product can be established. This advance significantly improves the shortcomings of the currently commercially available formulation, which requires the use of emulsifiers with hypersensitivity issues and requires pre-treatment with steroids prior to injection. On the other hand, due to the characteristics of nanosizing, the biodistribution of drugs in the body is changed, which greatly reduces the side effects of chemotherapy drugs. At the same time, due to its feature of being able to avoid P-Glycoprotein drug efflux pump, there is an opportunity for MPB-1734 to be used on patients who have developed chemo- resistance.

Additionally, MegaPro reports that in the animal model of head and neck cancer, it has been found that treatment with MPB-1734 can significantly increase immune cell infiltration into tumors (Ex: CD8+ T cells). The changes in the tumor microenvironment also reflect the synergistic benefit of the antitumor effect, as the tumor inhibition rate of the combined immuno-oncology agent MPB-1734 was significantly higher than that of the immuno-oncology agent monotherapy. and MPB-1734. There is a great potential opportunity for MPB-1734 to be combined with immunotherapy in the future. In addition to its own therapeutic effect, MPB-1734 can also change the tumor microenvironment from a cold tumor which was believed to be ineffective for immunotherapy to a warm tumor, achieving the best combined treatment effect.

MegaPro further states that MPB-1734 is currently in clinical trials for patients with advanced solid tumors. Going forward, the company will target ovarian cancer and head and neck cancer, which have a high recurrence rate. For those who cannot continue to receive additional treatment due to the severe side effects of neutropenia, MPB1734 may provide them with a new, usable drug. MegaPro plans to expedite the clinical study process by seeking designation of new forms of 505(b)(2) drugs and orphan drugs from the U.S. FDA, hoping to benefit patients by providing new opportunities for treatment.

About MegaPro Biomedical Co., Ltd. :

MegaPro Biomedical Co., Ltd. (stock code: 6827) was founded in 2014 and spun off from the Industrial Technology Research Institute. It is a new pharmaceutical technology company mainly engaged in the development of niche nano-medicines. MegaPro has two nanotechnology platforms – “Nanoparticles” and “Nanomicrocells”, developing nano iron oxide products. Currently, the fastest growing products are injectable iron supplements and liver cancer imaging agents for iron deficiency anemia. Currently, MegaPro has developed three major products, namely iron supplement MPB-1514 for iron deficiency anemia, contrast agent MPB-1523 for MRI diagnosis of hepatocellular carcinoma, and MPB-1734, a new dosage form of anti-cancer drug.

For more information about the company, please visit the official website:


This document and accompanying related information contain a predictive description. Excluding factual occurrences, all statements regarding future business operations, possible events, and prospects (including, but not limited to, forecasts, goals, estimates, and business plans) of MegaPro Biomedical Co., Ltd. (hereinafter referred to as the Company) are forward-looking statements. The forward-looking statement could be affected by various factors and uncertainties, causing the actual situation to differ materially. These factors include, but are not limited to, price fluctuations, actual demands, changes in exchange rates, market share, market competition, laws, finances and regulations. Structural changes, international economic and financial market conditions, political risks, cost estimates, etc., and other risks and variables are beyond the Company’s control. These forward-looking statements are predictions and assessments based on current conditions, and the Company is not responsible for any future updates.

File: MegaPro Biomedical MPB-1734 Receives Composition Patent for Novel Cancer Drug Dosage Form That Improved Combination Immunotherapy

11/15/2022 Distribution of a marketing press release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at

Comments are closed.